Theranostics refers to the combination of diagnostic biomarkers with therapeutic agents that
share a specific target expressed by diseased cells and tissues. Nuclear medicine is an …

Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …

The optimum selection of the appropriate radiolabelled probe for the right target and the
right patient is the foundation of theranostics in personalised medicine. In nuclear medicine …

The first clinical application of nuclear medicine treatments can be dated back to 1936, when
John H. Lawrence utilised an artificial radionuclide—phosphorus-32—to treat a case of …

Dear Sir, Thank you for the “Present and future of target therapies and theranostics: refining
traditions and exploring new frontiers-highlights from Annals of Nuclear Medicine 2021” that …

Nuclear medicine is experiencing a renaissance, with US Food and Drug Administration
approval recently being obtained for theranostic agents and a wide variety of such agents …

Recent years have witnessed a remarkable acceleration in radiopharmaceutical research
and development. The further integration of radiochemistry and nuclear medicine into …

In the last two decades, the demand for a personalized therapeutic approach has been
constantly increasing, mainly due to the need to develop ever more effective therapeutic …

Radiopharmaceuticals are increasingly playing a leading role in diagnosing, monitoring,
and treating disease. In comparison with conventional pharmaceuticals, the development of …

Wolfgang A. Weber and Johannes Czernin Scientific discoveries published in The Journal of
Nuclear Medicine over the past 60 years have shaped the practice of medicine and form the …